United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High at $317.95

United Therapeutics Co. (NASDAQ:UTHR)’s stock price hit a new 52-week high on Monday . The company traded as high as $317.95 and last traded at $312.44, with a volume of 20725 shares traded. The stock had previously closed at $316.04.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Wells Fargo & Company increased their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. HC Wainwright restated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Finally, The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $312.22.

United Therapeutics Price Performance

The business’s 50 day moving average is $266.47 and its two-hundred day moving average is $241.45. The firm has a market capitalization of $13.79 billion, a PE ratio of 14.94, a P/E/G ratio of 4.60 and a beta of 0.49. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period last year, the firm posted $4.86 earnings per share. As a group, research analysts anticipate that United Therapeutics Co. will post 24.61 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $287.22, for a total value of $1,033,992.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $37,338.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $287.22, for a total value of $1,033,992.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $37,338.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $32,282.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 144,728 shares of company stock valued at $36,072,597. 12.50% of the stock is currently owned by corporate insiders.

Institutional Trading of United Therapeutics

Hedge funds have recently modified their holdings of the business. Rise Advisors LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at $32,000. GAMMA Investing LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at $43,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares in the last quarter. Janiczek Wealth Management LLC boosted its holdings in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.